Equities

Jacobson Pharma Corporation Ltd

Jacobson Pharma Corporation Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.590
  • Today's Change0.00 / 0.00%
  • Shares traded228.00k
  • 1 Year change-13.93%
  • Beta0.6040
Data delayed at least 15 minutes, as of May 31 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jacobson Pharma Corporation Ltd is an investment holding company principally engaged in the manufacturing and sale of generic drugs. The Company operates its business through two segments. The Generic Drugs segment is engaged in the development, manufacture and distribution of a host of off-patent medicines for various therapeutic use. The Branded Healthcare segment is engaged in the development, manufactures and distributes branded medicines, proprietary Chinese medicines and health and wellness products. Currently the activities of two segments in this regard are primarily carried out in Hong Kong.

  • Revenue in HKD (TTM)1.68bn
  • Net income in HKD212.16m
  • Incorporated--
  • Employees1.59k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd909.68m160.21m851.58m848.005.320.53226.940.93610.2860.2861.622.860.35872.182.941,072,734.006.327.679.1210.4869.4078.7917.6120.681.51--0.05157.22-0.00495.38-23.43-1.67-1.14--
Brii Biosciences Ltd666.95k-188.98m853.88m128.00--0.2531--1,280.27-0.2598-0.25980.00094.620.0002----5,210.57-5.60---5.84-------29,881.69------0.001---98.80--63.90------
Zhongzhi Pharmaceutical Holdings Ltd2.22bn175.95m863.60m2.64k4.810.7622.990.38980.20770.20772.621.311.122.5310.54838,353.608.957.6914.1511.7559.7360.448.016.730.894--0.142442.4612.2612.4153.0013.8617.653.22
Fusen Pharmaceutical Co Ltd611.40m-39.21m892.45m1.15k--1.47--1.46-0.0525-0.05250.8130.81220.41991.958.36532,579.00-2.690.9678-5.541.7452.9551.95-6.422.590.60960.7560.379727.9515.024.13-4.83--0.2124--
JW (Cayman) Therapeutics Co Ltd187.93m-830.17m965.95m398.00--0.5279--5.14-2.02-2.020.45674.410.07041.6865.54472,190.20-31.11-39.77-35.21-44.0050.74---441.74-1,316.813.86-47.820.1592--19.32--9.23---19.87--
Sunho Biologics Inc-100.00bn-100.00bn1.11bn-------------------------------------------------------155.25------
Hbm Holdings Ltd699.66m178.21m1.12bn177.006.021.145.241.600.24240.24240.95331.280.38863.903.013,952,904.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61---12.62--
Jacobson Pharma Corporation Ltd1.68bn212.16m1.18bn1.59k5.300.49472.980.70120.11120.14090.88221.190.37222.877.50940,829.505.164.916.616.6042.0541.8113.8514.321.015.620.364635.9711.912.8941.304.42-6.226.39
Ascletis Pharma Inc61.18m-156.43m1.23bn219.00--0.4984--20.03-0.147-0.1470.0572.430.0222.303.86279,352.10-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04---20.44--
Jacobio Pharmaceuticals Group Co Ltd68.66m-388.19m1.24bn301.00--1.06--17.99-0.5022-0.50220.08881.470.0419--5.21228,115.30-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43--19.18--
VIVA Biotech Holdings2.33bn-125.51m1.34bn2.08k--0.333111.130.5751-0.0638-0.06381.201.860.28054.845.211,121,857.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.151.000.3412---9.4259.3178.03--31.98--
Mabpharm Ltd94.22m-226.31m1.42bn347.00--6.42--15.10-0.0549-0.05490.02290.05380.08930.11766.02271,520.80-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
Wuhan YZY Biopharma Co Ltd0.00-207.22m1.44bn123.00--10.47-----1.12-1.120.000.7118------0.00----------------1.41-100.120.4138-------1.50------
Essex Bio-Technology Ltd1.71bn275.26m1.46bn1.48k5.500.76124.370.8580.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
CStone Pharmaceuticals501.40m-396.97m1.49bn230.00--3.02--2.97-0.3147-0.31470.3970.38450.28112.443.722,179,981.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
Cryofocus Medtech Shanghai Co Ltd44.27m-105.38m1.53bn392.00--8.75--34.52-0.4407-0.44070.18510.73------112,921.90--------75.83---258.23--4.08--0.0597--50.83--13.13------
Data as of May 31 2024. Currency figures normalised to Jacobson Pharma Corporation Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.29%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 09 May 20244.71m0.24%
Dimensional Fund Advisors Ltd.as of 31 Mar 2024633.44k0.03%
Bessemer Investment Management LLCas of 31 Jan 2024205.92k0.01%
Lazard Asset Management LLCas of 30 Apr 2024126.00k0.01%
DFA Australia Ltd.as of 31 May 202365.24k0.00%
Nomura Asset Management Co., Ltd.as of 29 Mar 20245.23k0.00%
More ▼
Data from 31 Mar 2024 - 30 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.